drugset / Trial / NCT04626752
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma
Timeline
- Start
- 2020-04-01
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |